A provider toolkit with clinically relevant resources related to diagnosis and management of central precocious puberty.

CPP Provider Toolkit

A pair of experts in the management of diabetes review the role of insulin therapy and review the approval process for biosimilars, including the FDA's approval of the first interchangeable insulin biosimilar.

Interchangeable Insulin Biosimilars: A Game Changer in Diabetes Management

Podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP aimed at providing real-world perspective on the latest advances in diabetes management.

Following a historic National Diabetes Month, which included the approval of teplizumab and the release of STEP TEENS data, some may have expected the diabetes community might have a moment to digest this new information before the next major breakthroughs. This was not the case.

The month of December welcomed the US Food and Drug Administration’s clearance of the Dexcom G7 CGM system for all types of diabetes, the release of data confirming safety and efficacy of SGLT2 inhibitors in pediatric diabetes, updated Standards of Care in Diabetes, and more. In our December 2022 endocrinology month in review, our editorial team provides recaps and links to the most popular content of the month, which, in addition to the aforementioned topics, includes the release of new hypoglycemia guidelines from the Endocrine Society and a special edition episode of 

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives 

where hosts sit down with a member of the writing group for the updated ADA Standards of Care in Diabetes—2023.

Dexcom G7 CGM System Receives FDA Clearance

Dexcom has announced their Dexcom G7 Continuous Glucose Monitoring (CGM) system has received clearance from the US Food and Drug Administration for people with all types of diabetes aged 2 years and older.

Announced on December 8, the Dexcom G7 boasts an overall MARD of 8.2% and is billed by the company as the most covered CGM on the market.

Endocrine Society Releases Updated Guidance for Management of Hypoglycemia

The Endocrine Society has released a new clinical practice guideline aimed at outlining optimal evidence-based strategies for management of people with diabetes considered to be at high risk for hypoglycemia.

Released on December 7, the guideline, which was created by a multidisciplinary, 10-person team, is expected to be published in the March 2023 print issue of 

Journal of Clinical Endocrinology & Metabolism 

and is cosponsored by major organizations, including the American Association of Clinical Endocrinology and the American Diabetes Association (ADA).

Empagliflozin Proves Benefit in Pediatric Type 2 Diabetes in Phase 3 DINAMO Trial

New data suggests empagliflozin (Jardiance) use was associated with significant improvements in glycemic control among pediatric patients with type 2 diabetes.

Announced in a December 7 statement from Eli Lilly and Company, results of the phase 3 DINAMO trial indicate use of empagliflozin was associated with a statistically significant reduction in HbA1c and also with a clinically meaningful reduction in fasting plasma glucose among a population of patients aged 10-17 years of age living with type 2 diabetes.

American Diabetes Association Releases 2023 Standards of Care in Diabetes

The ADA has released their updated Standards of Care for 2023 with the goal of providing the diabetes care team within an overview of diabetes management, including updates in diabetes technology, obesity, hypertension, heart failure medication, and lipid management.

The 2023 version of the living document, which has been updated annually since 1989, contains more than 100 updated recommendations within its 17 sections, with new updates highlighting the latest advances in clinical aspects of diabetes management, such as pharmacologic approaches to glycemic treatment, but also related to holistic diabetes management, including patient-first language and the influence of social determinants of health.

Diabetes Dialogue: Updates in Inpatient Management of Diabetes, with Jane Jeffrie Seley, DNP, MPH

Not ones to let an opportunity for a timely spotlight episode pass them by, the hosts of 

Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with Jane Jeffrie Seley, DNP, MPH, a member of the writing group for the ADA’s Standards of Care in Diabetes—2023 at the ADCES DTC 22 the weekend preceding release to discuss the inpatient management section of the document and what went into formulating the recommendations.

Articles

The last full weekend of each month, our editorial team compiles a list of our most popular endocrinology content from the past month for a month in review recap. The December 2022 endocrinology month in review features coverage of the FDA’s clearance of Dexcom G7, new data related to use of SGLT2 inhibitors in pediatric type 2 diabetes, and the ADA's Standards of Care in Diabetes—2023. 

Endocrine Month in Review: December 2022

Although the year may be winding to a close, the diabetes community has still been moving ahead at a breakneck pace. In a year marked by historic advances, including the approval of tirzepatide (Mounjaro) and teplizumab (Tzield), the month of December has played host to the long-awaited US FDA clearance of the Dexcom G7 Continuous Glucose Monitoring System, the American Diabetes Association’s annual update of their Standards of Care in Diabetes, and the Association of Diabetes Care and Education Specialists (ADCES) Diabetes Technology Conference.

To bring the year to a close, the hosts of 

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the CGM Program Coordinator at the Cleveland Clinic, and Natalie Bellini, DNP, an endocrine nurse practitioner at R&B Medical Group, sat down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

 is available in an audio-only format on 

In the December 2022 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

Diabetes Dialogue: December 2022

 was placed almost solely in the hands of endocrinologists. Over time, a physician shortage, combined with a growing burden of diabetes on a population level, has led to a revolution in the diabetes care team.

No organization is more representative of this evolution than the Association of Diabetes Care and Education Specialists (ADCES). Founded in 1973 as the American Association of Diabetes Educators, the multidisciplinary organization has sought to improve diabetes management since its inception through an emphasis on holistic management and the continuum of care. As a result, the organization’s membership includes pharmacists, nurse practitioners, physician associates, dietitians, psychologists, and more.

Among these members is Jill Weissberg-Benchell, PhD, CDCES, a pediatric psychologist in the Pritzker Department of Psychiatry and Behavioral Health and professor of Psychiatry and Behavioral Sciences at Northwestern University Feinberg School of Medicine. Weissberg-Benchell’s journey into the diabetes community is unique and occurred later in her career relative to some of her counterparts. Since developing an interest in diabetes management, Weissberg-Benchell has led or took part in research endeavors exploring self-management behaviors and use of diabetes technology.

During their time at the ADCES Diabetes Technology Conference 2022 in Chicago, Diana Isaacs, PharmD, and Natalie Bellini, DNP, hosts of 

, sat down with Weissberg-Benchell to record a special edition episode. In the episode, Weissberg-Benchell takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in management of diabetes.

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

Diabetes Dialogue: The Psychology of Diabetes Management, with Jill Weissberg-Benchell, PhD

Few names are carried in the same esteem within the diabetes community as Richard Bergenstal, MD. The former president of Science and Medicine with the American Diabetes Association, Bergenstal served as the principal investigator for multiple landmark trials that have contributed to current standards of care in both type 1 and type 2 diabetes, including the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes, the Action to Control Cardiovascular Risks in Diabetes (ACCORD) study, and the Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) study.

Currently serving as an endocrinologist and Executive Director of the International Diabetes Center, Bergenstal has been a champion of advancing diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, since the advent of these technologies. During his time at the Association of Diabetes Care and Education Specialists Diabetes Technology Conference 2022 in Chicago, Bergenstal sat down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special edition episode of 

Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives

In the episode, Bergenstal discusses the role and evolution of continuous glucose monitoring and automated insulin delivery systems, as well as other technologies, in the management of diabetes. Later, Bergenstal offers perspective on ongoing research and future needs as the field looks to optimize the application of these technologies.

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

Diabetes Dialogue: The History and Future of Diabetes Technology, with Richard Bergenstal, MD

The US Food and Drug Administration (FDA) has approved abaloparatide (Tymlos) as a treatment for 

Radius Health Inc. statement on December 20

, the approval, which is based on results of the phase 3 ATOM study, indicates the parathyroid hormone related peptide for increasing bone density in men with osteoporosis at high risk of fracture or in patients who have failed or are intolerant to other available osteoporosis therapies.

“TYMLOS has been helping postmenopausal women with osteoporosis at high risk for fracture for over five years. We are excited that with this approval, we can bring TYMLOS to a new population,” said Chhaya Shah, Chief Business Officer at Radius, in the aforementioned statement. “We are grateful to the men who participated in the ATOM study, as they played a pivotal role in helping bring this important treatment to men with osteoporosis at high risk of fracture.”

A randomized, double-blind, placebo-controlled, 12-month multicenter trial, the Abaloparatide Treatment of Men (ATOM) study was designed to determine the efficacy and safety of abaloparatide 80 micrograms in men with osteoporosis and were announced in October 2022. With a primary efficacy endpoint of the percent change from baseline in bone mineral density at the lumbar spine at 12 months, results of the study demonstrated use of abaloparatide was associated with a mean increase in BMD of 8.5% compared to 1.2% among patients receiving the placebo.

Abaloparatide had previously received approval from the FDA for treatment of postmenopausal women with osteoporosis at high risk for fracture based on the phase 3 ACTIVE study in April 2017. In the ACTIVE trial, use of abaloparatide was associated with a statistically significant 86% relative risk reduction of new vertebral fracture at 18 months compared against placebo therapy (

“Radius stands behind our commitment to the bone health community and with this approval, men with osteoporosis at high risk for fracture will have an additional important treatment option,” added Scott Briggs, Chief Executive Officer at Radius.

In the aforementioned statement, Radius Health noted the most common adverse reactions reported with abaloparatide in men with osteoporosis were injection site erythema (13%), dizziness (9%), arthralgia (7%), injection site swelling (7%), injection site pain (6%), contusion (3%), abdominal distention (3%), diarrhea (3%), nausea (3%), abdominal pain (2%), and bone pain (2%). In postmenopausal women, the most common adverse reactions were hypercalciuria (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), fatigue (3%), upper abdominal pain (3%), and vertigo (2%).

Announced by Radius Health on December 20, the US FDA approval for abaloparatide (Tymlos) indicates the agent as a treatment to increase bone density in men with osteoporosis at high risk of fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.

Abaloparatide Receives FDA Approval for Osteoporosis in Men

The year of 2022 will be remembered as one that ushered in a new era of diabetes management. With the approvals of tirzepatide and teplizumab dominating headlines, several other advances in the field caught the attention of millions and became topics of discussion. To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content from 2022.

Tirzepatide (Mounjaro) Now Available in US Pharmacies, Ushering in New Era of Glucose-Lowering

Beginning on June 7, tirzepatide (Mounjaro) will be available in US pharmacies, according to an announcement by Eli Lilly and Company.

Announced on the final day of the American Diabetes Association (ADA) 82nd Scientific Sessions, Eli Lilly and Company noted the dual GIP/GLP-1 receptor agonist, which received approval from the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, will be made available 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses.

Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022

After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.

The American Diabetes Association has released their updated Standards of Care for 2023 with the goal of providing the diabetes care team within an overview of diabetes management, including updates in diabetes technology, obesity, hypertension, heart failure medication, and lipid management.

Dexcom Announces Global Launch of Dexcom G7 Glucose Monitoring System

The Dexcom G7 Continuous Glucose Monitoring (CGM) System rollout began on October 4 with the company announcing its availability for people with diabetes aged 2 years and older in the United Kingdom, Ireland, Germany, Austria, and Hong Kong, with a rollout in New Zealand and South Africa expected within the following weeks.

Study Finds Dexcom G7 Setup is Easier, Requires Fewer Tasks for Older Adults than Previous Generations

A formal task analysis conducted in older adults with type 2 diabetes provides insight into the ease of use and task burden associated with uptake of the Dexcom G7 CGM system, with results indicating use of the system required fewer than half as many steps to initiate as previous generations of the CGM system.

Medicare Advantage Beneficiaries Less Likely to Receive Newer Diabetes Medications

An analysis comparing prescribing practices for Medicare Advantage beneficiaries against those in fee-for-service programs suggests Advantage patients were more likely to receive ACE inhibitors or ARBs, but 20% less likely to receive GLP-1 RAs and 9% less likely to receive SGLT2 inhibitors.

Real-World Data Backs 2.4 mg Semaglutide (Wegovy) for Weight Management in Obesity

After demonstrating efficacy and safety as a weight loss agent in randomized clinical trials, a retrospective cohort study from a Mayo Clinic-led team is providing insight into the real-world effects of 2.4 mg semaglutide (Wegovy) for weight management.

With data from more than 150 patients treated at a referral center for weight management prescribed semaglutide for 3 months or more between January 1, 2021-March 15, 2022, results of the study suggest the mean weight loss achieved at 3 months was 5.9% of body weight, with this improving to 10.9% at 6 months and further analysis indicating more than 50% of semaglutide users achieving weight loss of 10% or more at 6 months.

North American Menopause Society Updates Hormone Therapy Guidance

The North American Menopause Society has announced the release of a new position statement outlining the organization’s stance on hormone therapy.

Published on July 7, the statement was published with the intent of providing clinicians and patients with an update to the organization’s 2017 position statement on the same topic and has been endorsed by more than 20 international organizations, including the American Association of Clinical Endocrinology and the American Medical Women’s Association.

To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content related to endocrinology from 2022.

Top News in Endocrinology for 2022

Our editorial team is celebrating the final week of the year by recapping some of our most popular stories and content from the past year. Here, we are highlighting our most popular content related to diabetes technology from 2022. Of note, this list does not include regulatory news or guideline recommendations as both of these topics were covered in their own year in review recaps.

Most Popular Content in Diabetes Technology

New data from a small study assessing ease of uptake of the Dexcom G7 continuous glucose monitoring system is underlining the impact of advancing technology on accessibility and use of newer CGM systems as part of diabetes management.

A 10-person study assessing uptake of the Dexcom G7 CGM system among a population of older adults with the aid of a certified diabetes care and education specialist, results indicate that G7 CGM system required half as many steps to set up and deploy as the G6 system, with the system’s system usability scale survey scores indicating excellent usability.

Diabetes Dialogue: Optimizing CGM Uptake in Primary Care

In the first of 4 special edition episodes from ADA 2022, 

 hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics’ Insulin-Only Bionic Pancreas.

iLet Bionic Pancreas Improves Glycemic Control, Time in Target Range in Type 1 Diabetes

Full data from the 13-week trial of the iLet insulin-only bionic pancreas details the improvements in glycemic control achieved with use of the bionic pancreas in adults and children with type 1 diabetes aged from as young as 6 years old and up to 79 years of age.

With funding from the National Institute of Diabetes and Digestive and Kidney Diseases, results of the 13-week randomized trial suggest use of BetaBionics’ iLet bionic pancreas was associated with greater reductions in HbA1c than standard care, with those using a bionic pancreas experience a greater percentage of time in range as well.

Increased Scanning Frequency Improves Glucose Control, Hypoglycemia Fear in T1D Using CGM

Increased scanning can decrease fear of hypoglycemia among people with type 1 diabetes using intermittently scanned CGM systems, according to the results of a new study.

An analysis of clinical data and ambulatory glucose profile reports from an outpatient clinic in Poland, results of the study indicate increased frequency of scanning with intermittently scanned CGM devices was associated with improve glycemic control and decreased fear of hypoglycemia among people with type 1 diabetes.

Our editorial team is celebrating the end of 2022 by recapping our most popular content related to diabetes technology from the past year.

Top News in Diabetes Technology for 2022

With less than a week to go until the close of 2022, our editorial team is celebrating the final week of the year by recapping some of our most popular stories and content from the past year. Here, we are highlighting our most popular content related to new guidelines and recommendations related to diabetes management from 2022. Our recap includes the 2023 Standards of Care, USPSTF recommendation on type 2 diabetes screenings in adolescents, recommendations for pharmacologic management of obesity, new bariatric surgery guidance, and a consensus report on use of automated insulin delivery.

USPSTF Issues First Recommendation Statement on Type 2 Diabetes Screening in Children and Adolescents

The US Preventive Services Task Force has released their first recommendation statement outlining the organization’s stance on screening for prediabetes and type 2 diabetes in children and adolescents without known diabetes or prediabetes or without symptoms of either.

Released on September 13, the USPSTF concluded in their recommendation statement, which is the first on the subject for this particular patient population, that there was insufficient evidence to assess the balance of benefits and harms of screening for type 2 diabetes or prediabetes in children and adolescents, awarding an I grade to the statement.

American Gastroenterological Association Releases Guidelines for Pharmacologic Management of Obesity

The American Gastroenterological Association has released new guidance outlining the organization’s stance on evidence-based approaches to management of obesity using pharmacological interventions.

Released on October 20, the document, which was composed by a multidisciplinary panel of content experts and guideline methodologists using the GRADE framework, endorses multiple semaglutide 2.4 mg (Wegovy), phentermine-topiramate ER (Qsymia), liraglutide 3 mg (Saxenda), and naltrexone-bupropion ER (Contrave) as first-line medical therapies in addition to diet and exercise for weight loss in people with obesity.

American, International Organizations Debut New Bariatric and Metabolic Surgery Guidelines

After a more than 30-year wait, bariatric and metabolic surgeons have a new set of international, evidence-based guideline recommendations for weight loss surgery.

Published on October 21 by the American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), the guideline recommendations were created with the intent of replacing those developed for the 1991 consensus statement from the National Institutes of Health and include multiple changes, including expanding the patient population for metabolic and bariatric surgery to include patients with type 2 diabetes and a BMI of 30 kg/m2 or greater.

American Diabetes Association, EASD Publish Joint Consensus Report on Automated Insulin Delivery

The American Diabetes Association and the European Association for the Study of Diabetes have released a new consensus report aimed at providing evidence-based recommendations as well as an overview of the benefits and challenges with automated insulin delivery.

Published on October 6, the document reflects the rapid advancement of AID technology in recent years and was composed by a joint Diabetes Technology Working Group, the same group that wrote the organizations' first consensus report on insulin pumps in 2015.

Our recap of new guidelines and recommendations related to diabetes management from 2022 includes the 2023 Standards of Care, USPSTF recommendation on type 2 diabetes screenings in adolescents, recommendations for pharmacologic management of obesity, new bariatric surgery guidance, and a consensus report on use of automated insulin delivery.

Top New Cardiometabolic Health Guidelines/Recommendations in 2022

In March 2022, together with Diana Isaacs, PharmD, and Natalie Bellini, DNP, we launched 

Born to serve as a monthly podcast providing clinically applicable takeaways from the latest updates in the space, the rapid rate of advancement and news in diabetes management resulted in the creation of more than 20 episodes, including multiple special edition and on-site episodes at major meetings featuring guests and tackling historic topics, such as the approval of teplizumab. To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.

In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.

In the first of 4 special edition episodes recorded at ADA 2022, our hosts take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics’ Insulin-Only Bionic Pancreas.

Diabetes Dialogue: What Teplizumab Means for Type 1 Diabetes

In this special edition episode of Diabetes Dialogue, our hosts break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

Diabetes Dialogue: Inside ADA 2022, with Diana Isaacs, PharmD, and Natalie Bellini, DNP

In their fourth and final episode from ADA 2022, our hosts take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

, host provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

Dr. Natalie Bellini’s Top 5 Picks for 2022

During their time on site at ADCES 22 in Baltimore, MD, our hosts recorded 4 episodes with special guests. In this article, readers will find a collection of the on-site coverage from the annual meeting, including sit-down conversations with Korey Hood, PhD; Jennifer Clements, PharmD; Anastasia Albanese-O’Neill, PhD; and David Walton.

Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, and Misdiagnosis of T1D

In this episode, hosts discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

In the December 2022 episode, hosts sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.



Diabetes Dialogue: 2022 Year in Review

With less than a week to go until the close of 2022, our editorial team is kicking off the final week of the year by recapping some of our most popular stories and content from the past year. 

Here, we are highlighting the most popular regulatory news from the past year. For our readers, we’ve broken down this list into top diabetes drug approvals and top diabetes technology clearances. Below, you will find a brief recap of each and links to any associated coverage.

Tirzepatide (Mounjaro) Wins FDA Approval for Type 2 Diabetes

The US Food and Drug Administration has granted approval to tirzepatide (Mounjaro) as an adjunct therapy to diet and exercise for improving glycemic control in adults with type 2 diabetes, according to a 

Announced on May 13, approval of the first-in-class, once-weekly dual GLP-1/GIP agonist, which is expected to be available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses, is based on data from the SURPASS program.

The US Food and Drug Administration has approved a 2 mg dose of semaglutide (Ozempic) for use in patients with type 2 diabetes, according to a 

Announced on March 28, the approval for the 2 mg dose of Novo Nordisk’s once-weekly GLP-1 RA is approved as an adjunct therapy to accompany diet and exercise for improving blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and a history of cardiovascular disease.

Teplizumab Receives FDA Approval for Delaying Type 1 Diabetes

The fight against diabetes has taken a historic turn, with the US Food and Drug Administration approval of teplizumab (Tzield) injection to delay the onset of type 1 diabetes in adults and pediatric patients.

, the FDA’s approval indicates the anti-CD3 antibody from Provention Bio, which will be marketed through a partnership with Sanofi, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

Top Clearances in Diabetes Technology for 2022

Omnipod 5 Receives Clearance for Use in Ages 2 and Older with Type 1 Diabetes

The US Food and Drug Administration has approved the Omnipod 5 Automated Insulin Delivery System for use in individuals aged 6 years and older with type 1 diabetes, according to a 

Announced on January 28, Insulet suggests the approval Omnipod 5 the first tubeless automated insulin delivery system with the ability to integrate with the Dexcom G6 continuous glucose Monitoring System and a compatible smartphone to automatically adjust insulin and protect against glycemic events.

FreeStyle Libre 3 Receives FDA Clearance for Diabetes in Patients 4 Years and Older

The FreeStyle Libre 3 system from Abbott has received clearance from the US Food and Drug Administration for use by people aged 4 years and older living with diabetes.

, the FreeStyle Libre 3 is expected to be available later this year at participating pharmacies and will be available at the same price as previous versions of the system.

Diabetes Dialogue: EASD 2022 and CGM News

US FDA Approves Eversense E3 CGM System, Allows Use for Up to 6 Months

The US Food and Drug Administration has approved the Eversense E3 Continuous Glucose Monitoring System, which uses proprietary sacrificial boronic acid (SBA) technology to extend longevity to 6 months, according to a 

The company noted plans for the Eversense E3 to be available to patients in the US through Ascensia Diabetes Care beginning in the second quarter of 2022.

PROMISE Study Provides Insight into Safety, Accuracy of Eversense 180-Day CGM System

Our editorial team is kicking off the final week of the year by recapping our the most talked about approvals and clearances related to diabetes management from the US Food and Drug Administration in 2022, including tirzepatide, teplizumab, Dexcom G7, and more!